Paris-based Lucis, a preventive-health platform that pairs blood biomarker testing with an AI-driven companion app, has raised a $20m Series A led by Singular, with participation from General Catalyst, Y Combinator and angel investors including Céline Lazorthes of Resilience, Manu Lecomte, and backers of the running-coach app Runna.
The round arrives four months after the company’s $8.5m seed in December 2025, bringing total funding to roughly $28m. Lucis says the capital will fund expansion into Spain, Germany and Italy by the end of 2026 and continued development of the AI layer that turns biomarker data into ongoing health guidance. The company will not disclose its valuation.
Lucis was founded in 2025 by Maxime Berthelot, Baptiste Debever and Max Guérois, and went through Y Combinator’s 2025 batch. Its model is simple to describe and increasingly familiar: members get a blood draw at a partner laboratory, the platform analyses what the company says is more than 110 biomarkers across metabolic, hormonal, cardiovascular, inflammatory and nutritional systems.
Then the results feed an AI companion that recommends nutrition, supplementation, lifestyle and follow-up testing changes, with physician oversight. Recommendations refine as new data arrives. Lab partners include Eurofins and Randox.
